- The ECJ has ruled that payments pharmaceutical companies make to public health insurers, whether as discounts, contributions, or mandatory payments, are considered rebates that reduce the VAT taxable amount.
- These rulings apply even if the payments are not labeled as commercial discounts and regardless of whether invoices are issued, as long as documentation proves the payment.
- The principle was confirmed in multiple cases (Germany, Hungary, and Novo Nordisk in 2024), establishing that such payments lower the actual price received by the producer and thus the VAT base.
- The decisions ensure fiscal neutrality and proportionality, allowing pharmaceutical companies across the EU to reclaim VAT where appropriate.
Source: meridianglobalservices.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
Latest Posts in "European Union"
- EU Weighs VAT Reform for Financial Services Amid Crypto and Fintech Growth
- ECJ VAT Case – C-512/26 (Commission v Spain) – Action – VAT rates reform: failure to transpose Directive (EU) 2022/542
- ECJ VAT Case – C-504/26 (Commission v Spain) – Action – Small enterprises VAT scheme: failure to transpose Directive (EU) 2020/285
- New European Court VAT Case – T-520/26 (Frexport) – No details known yet
- New European Court VAT Case – T-519/26 (Liege Cargo Agency) – No details known yet
